Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 14/20 | 0.68 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.68 |
| ▸ | FGFR3 | P22607 | 14/20 | 0.68 |
| ▸ | KDR | P35968 | 10/20 | 0.68 |
| ▸ | FLT1 | P17948 | 9/20 | 0.68 |
| ▸ | FLT4 | P35916 | 9/20 | 0.68 |
| ▸ | SRC | P12931 | 4/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | CSK | P41240 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCH | P24723 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25779717 | 0.86 | FGFR1 (0.73) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL6056003 | 0.82 | FGFR1 (0.70) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL29828472 | 0.81 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL177946 | 0.81 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22130753 | 0.79 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30738006 | 0.79 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22144559 | 0.78 | FGFR1 (0.95) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL19338047 | 0.77 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4076530 | 0.77 | FGFR1 (0.88) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16489372 | 0.77 | FGFR1 (0.91) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | claimed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | claimed |
| US-10736900-B2 | Combinations of an FGFR inhibitor and an IGF1R inhibitor | ASTEX THERAPEUTICS LTD (GB) | 2020-08-11 | — | — | US | disclosed |
| US-10464939-B2 | Deuterated triazolopyridazine as a kinase modulator | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-05 | — | — | US | disclosed |
| US-20190031670-A1 | DEUTERATED TRIAZOLOPYRIDAZINE AS A KINASE MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| EP-3411048-A1 | METHODS OF DIFFERENTIATING STEM CELL-DERIVED ECTODERMAL LINEAGE PRECURSORS | Memorial Sloan-Kettering Cancer Center (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017136834-A1 | METHODS OF DIFFERENTIATING STEM CELL-DERIVED ECTODERMAL LINEAGE PRECURSORS | MEMORIAL SLOAN-KETERING CANCER CENTER (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170100406-A1 | COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR | ASTEX THERAPEUTICS LTD (GB) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | FGFR1 4648/4885FGFR2 4411/4885FGFR4 4585/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | FGFR1 4648/4885FGFR2 4411/4885FGFR4 4585/4885 |
| US-10464939-B2 | Deuterated triazolopyridazine as a kinase modulator | MET, DMPK, ABL1 | FGFR1 131/4885FGFR2 405/4885FGFR4 426/4885 |
| US-20170100406-A1 | COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR | IGF1R, FGFR3, FGFR1 | FGFR1 3/4885FGFR2 4/4885FGFR4 5/4885 |
| US-20190031670-A1 | DEUTERATED TRIAZOLOPYRIDAZINE AS A KINASE MODULATOR | MET, DMPK, ABL1 | FGFR1 131/4885FGFR2 405/4885FGFR4 426/4885 |
| US-10736900-B2 | Combinations of an FGFR inhibitor and an IGF1R inhibitor | IGF1R, FGFR3, FGFR1 | FGFR1 3/4885FGFR2 4/4885FGFR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.